Sylvestre Grizot

Title: Sylvestre Grizot: Innovator in Genetic Engineering

Introduction

Sylvestre Grizot is a notable inventor based in La Garenne Colombes, France. He has made significant contributions to the field of genetic engineering through his innovative work. His expertise lies in the development of advanced meganucleases, which have important applications in genome therapy and antiviral therapy.

Latest Patents

Grizot holds a patent for a new I-CreI derived single-chain meganuclease. This invention comprises two domains, each derived from a parent I-CreI monomer. These domains extend from the beginning of the first alpha helix to the end of the C-terminal loop. They are joined by a peptidic linker that allows them to fold as an I-CreI dimer. This dimer is capable of binding and cleaving a chimeric DNA target, which includes different halves of each parent homodimeric I-CreI meganuclease target sequence. The applications of this I-CreI derived single-chain meganuclease are vast, including uses in genetic engineering, genome therapy, and antiviral therapy. Grizot has been granted 1 patent for this innovative work.

Career Highlights

Throughout his career, Sylvestre Grizot has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Cellectis S.A. and Cellectis. His work in these organizations has furthered the development of genetic engineering technologies.

Collaborations

(Section skipped due to space constraints.)

Conclusion

Sylvestre Grizot is a pioneering inventor whose work in genetic engineering has the potential to transform therapeutic approaches. His innovative patent for a single-chain meganuclease exemplifies his contributions to the field.